Clik here to view.
GI CELL Enters Agreement with Optieum Biotechnologies
SEONGNAM, South Korea GI CELL, Inc. announced today that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. (Japan). Under the agreement, Optieum...
View ArticleClik here to view.
マシモが敗血症指標の限定的な市場投入を発表
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、マシモ・ペイシェント・セーフティーネット（Masimo Patient SafetyNet™）で遠隔モニタリングされている患者において、臨床医が敗血症の可能性を確認できるように設計された早期警告指標の敗血症指標（Sepsis...
View ArticleClik here to view.
Masimo宣布在有限市场发布脓毒症指数
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天宣布在有限市场发布脓毒症指数(Sepsis Index, Si™)。这是一项早期预警指标，旨在帮助临床医生识别受Masimo Patient SafetyNet™远程监测的患者的脓毒症风险。Patient...
View ArticleClik here to view.
武田将在美国血液学会(ASH)第64届年会上呈报数据，彰显对血液系统癌症和其他血液病患者的承诺
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田(TSE:4502/NYSE:TAK)今天宣布，将于2022年12月10日至13日在新奥尔良召开的美国血液学会(ASH)第64届年会上呈报15篇公司赞助的摘要。武田的最新研究侧重于改善血液病患者的长期转归。 武田的呈报将包括口头报告会，届时将详细介绍3期OPTIC试验的三年更新结果，展示ICLUSIG®...
View ArticleClik here to view.
武田薬品、第64回米国血液学会（ASH）年次総会で血液がんおよび他の血液疾患の患者へのコミットメントを示すデータを発表へ
大阪 & 米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — 武田薬品（TSE:4502/NYSE:TAK）は本日、2022年12月10～13日にニューオーリンズで開催される第64回米国血液学会（ASH）年次総会において、企業スポンサー研究のアブストラクト15件を報告すると発表しました。武田薬品の最新の研究では、血液疾患の患者の長期転帰改善に重点を置いています。...
View ArticleClik here to view.
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today presented the final progression-free survival (PFS)...
View ArticleClik here to view.
athenahealth Expands its Global Corporate Social Responsibility Program in 2022
WATERTOWN, Mass. athenahealth, Inc., a leading provider of network-enabled software and services for medical groups and health systems nationwide, today announced that its athenaGives corporate...
View ArticleClik here to view.
知临集团宣布完成交易 2023 年到期的 300 万美元可转换票据
NEW YORK & LONDON & PARIS (美国商业资讯)– 知临集团有限公司（纳斯达克股票代码：APM，巴黎泛欧证券交易所股票代码：APM）（“知临集团”或“知临”），一家致力于满足肿瘤、自身免疫性疾病和传染病领域未被满足的医疗需求的临床阶段生物制药公司，今天宣布已完成交易私募发售本金总额为300万美元...
View ArticleClik here to view.
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
NEW YORK & LONDON & PARIS Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to...
View ArticleClik here to view.
百奥赛图自研双抗获FDA批准进入临床试验
中国北京 (美国商业资讯)- 百奥赛图（北京）医药科技股份有限公司（“百奥赛图”，股票代码02315.HK）宣布其自主研发的全球首创双特异性抗体YH008（PD-1 x CD40）的IND申请获得美国FDA批准。此次IND申报由百奥赛图全资子公司祐和医药完成。...
View ArticleClik here to view.
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody...
BEIJING Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of...
View ArticleClik here to view.
ENHERTU® Approved in the EU for Patients with Previously Treated HER2...
TOKYO & MUNICH Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the...
View ArticleClik here to view.
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2...
TOKYO & MUNICH Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy...
View ArticleClik here to view.
REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute...
TAIPEI, Taiwan REGiMMUNE Limited, a clinical-stage biopharmaceutical company developing innovative immunotherapies for immune disorders and cancer, today announced the positive results of their...
View ArticleClik here to view.
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV®...
BOTHELL, Wash. & TOKYO & RAHWAY, N.J. Seagen Inc. (Nasdaq: SGEN), Astellas Pharma Inc. (TSE:4503) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced...
View ArticleClik here to view.
バイオサイトジェン、二重特異性抗体YH008のIND申請をFDAが承認したと発表
北京 （ビジネスワイヤ） — バイオサイトジェン・ファーマシューティカルズ（北京）（以下「バイオサイトジェン」、HKEX: 02315）は本日、ファーストインクラスの自社開発PD-1 x...
View ArticleClik here to view.
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today that the Company has received approval from the Center for Drug Evaluation (CDE) to conduct a single-arm, open-label, multi-cohort...
View ArticleClik here to view.
Conrad N. Hilton Foundation Awards more than $175 million from April through...
WESTLAKE VILLAGE, Calif. The Conrad N. Hilton Foundation announced today that the board of directors approved more than $175 million, including program-related investments, in the second and third...
View ArticleClik here to view.
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory...
SANTA MONICA, Calif. & TOKYO Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced...
View ArticleClik here to view.
Elpiscience Announces CDE IND Clearance of ES014, a First in Class...
SHANGHAI & SUZHOU, China & GERMANTOWN, Md. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation...
View Article